340b | Clinical Oncology: ASCO, COA to Congress: Part B Drug Model Is Bad Medicine
16299
single,single-post,postid-16299,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-9.1.3,wpb-js-composer js-comp-ver-4.11.1,vc_responsive

23 Sep Clinical Oncology: ASCO, COA to Congress: Part B Drug Model Is Bad Medicine

Representatives of the American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) urged Congress to stop a Medicare Part B demonstration project, which they say will have a detrimental effect on cancer patients’ access to care, in testimony to the U.S. House of Representatives Committee on the Budget on Sept. 7.

The Center for Medicare & Medicaid Innovation’s (CMMI)-proposed Part B demonstration project would reduce reimbursement rates to oncology practices through the Average Sales Price (ASP) formula from ASP plus 6% to ASP plus 2.5% with an additional $16.80 flat fee per drug per day. According to ASCO, budget sequestration would further reduce the rate of reimbursement to ASP plus 0.86% and a flat fee of $16.53 per drug per day.

Read More